To date, three small-molecule PSMA inhibitors from this group, [68Ga]Ga-PSMA-11, [18F]F-DCFPyL, and Flotufolastat F-18, have been approved for PET visualizations of prostate cancer by the Food and Drug Administration; [18F]F-PSMA-1007 is awaiting regulatory approval in European countries pending a phase 3 clinical study being completed; and [99mTc]Tc-MIP-1404 has been reported to be a promising SPECT agent [11,12]. This evidence concerns the gene FOLH1 and prostate cancer.